{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:16:25Z","timestamp":1787008585847,"version":"build-2736575974"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite therapeutic advances for hidradenitis suppurativa (HS), specialist multidisciplinary services remain limited. The HS UK and Ireland Network (H-SKIN) seeks to advance evidence-based management and optimize outcomes through collaborative clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To examine variations in the management of HS and access to treatment between specialist and nonspecialist services.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An online survey, open from April to August 2025, explored clinical practice in HS management. The survey questionnaire was distributed to clinicians via H-SKIN, the British Association of Dermatologists (BAD) and the British Dermatological Nursing Group (BDNG) networks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 99 questionnaires were completed (38 H-SKIN; 61 BAD\/BDNG). Medication use varied, with the largest differences reported in metformin (89% H-SKIN; 62% BAD\/BDNG), secukinumab (92% H-SKIN; 52% BAD\/BDNG) and spironolactone use (71% H-SKIN; 46% BAD\/BDNG). Deroofing and wide local excision were available to 42% and 84% of the H-SKIN group, respectively, compared with 23% and 70% in the BAD\/BDNG group. Pain scores were recorded more often in the H-SKIN group than the BAD\/BDNG group (61% vs. 29%, respectively). Mental health screening was conducted by 89% of the H-SKIN group and 69% of the BAD\/BDNG group. Psychological support was available to 37% of the H-SKIN group compared with 8% of the BAD\/BDNG group. In the BAD\/BDNG group, 79% of respondents had no access to a multidisciplinary team (MDT) to discuss patients with HS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results highlight disparities in the UK and Ireland regarding access to HS medical treatments, deroofing and MDT support. Improvements in the standardization of care are needed. The new national HS MDT organized by H-SKIN will help facilitate this by improving access to specialist support.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag132","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:49:28Z","timestamp":1773330568000},"page":"1433-1441","source":"Crossref","is-referenced-by-count":2,"title":["Secondary care management of patients with hidradenitis suppurativa in the United Kingdom and Ireland: a survey of current practice"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4521-2907","authenticated-orcid":false,"given":"Hannah E","family":"Wainman","sequence":"first","affiliation":[{"name":"Centre for Applied Excellence in Skin & Allergy Research, University of Bristol , Bristol ,","place":["UK"]},{"name":"Bristol Dermatology Centre, Bristol Royal Infirmary, University Hospitals Bristol and Weston NHS Foundation Trust , Bristol ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-1142","authenticated-orcid":false,"given":"John R","family":"Ingram","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University , Cardiff ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"2026072409174228700_llag132-B1","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/jamadermatol.2025.2373","article-title":"Prevalence of hidradenitis suppurativa: a meta-analysis of global hidradenitis suppurativa atlas studies","volume":"161","author":"Bouazzi","year":"2025","journal-title":"JAMA Dermatol"},{"key":"2026072409174228700_llag132-B2","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/bjd.19435","article-title":"The epidemiology of hidradenitis suppurativa","volume":"183","author":"Ingram","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026072409174228700_llag132-B3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life","volume":"35","author":"Nguyen","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026072409174228700_llag132-B4","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/bjd.20523","article-title":"Thematic synthesis of the experiences of people with hidradenitis suppurativa: a systematic review","volume":"185","author":"Howells","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026072409174228700_llag132-B5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijwd.2020.02.006","article-title":"Integrated multidisciplinary approach to hidradenitis suppurativa in clinical practice","volume":"6","author":"Touhouche","year":"2020","journal-title":"Int J Womens Dermatol"},{"key":"2026072409174228700_llag132-B6","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s00403-023-02645-y","article-title":"Assessing unmet needs in patients with hidradenitis suppurativa","volume":"315","author":"Chadha","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"2026072409174228700_llag132-B7","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/bjd.17537","article-title":"British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018","volume":"180","author":"Ingram","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026072409174228700_llag132-B8","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/ced.14598","article-title":"British Association of Dermatologists National Clinical Audit on the Management of Hidradenitis Suppurativa in the UK","volume":"46","author":"Hasan","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"2026072409174228700_llag132-B9","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/bjd.13866","article-title":"Management of hidradenitis suppurativa: a U.K. survey of current practice","volume":"173","author":"Ingram","year":"2015","journal-title":"Br J Dermatol"},{"key":"2026072409174228700_llag132-B10","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/bjd.19302","article-title":"What has changed in the UK management of hidradenitis suppurativa from 2014 to 2019?","volume":"183","author":"Hasan","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026072409174228700_llag132-B11","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/jdv.20472","article-title":"European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: Treatment","volume":"39","author":"Zouboulis","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026072409174228700_llag132-B12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09546634.2019.1592100","article-title":"Metformin use in hidradenitis suppurativa","volume":"31","author":"Jennings","year":"2020","journal-title":"J Dermatol Treat"},{"key":"2026072409174228700_llag132-B13","doi-asserted-by":"crossref","first-page":"3094642","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediators Inflamm"},{"key":"2026072409174228700_llag132-B14","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.jaad.2025.06.077","article-title":"Glucagon-like peptide-1 receptor agonists in the adjunctive treatment of patients with hidradenitis suppurativa: a systematic review","volume":"93","author":"S\u00e1nchez-Feliciano","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"2026072409174228700_llag132-B15"},{"key":"2026072409174228700_llag132-B16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/bjd\/ljaf151","article-title":"The association between hidradenitis suppurativa and psychiatric disease: a systematic review and meta-analysis","volume":"193","author":"Folkmann","year":"2025","journal-title":"Br J Dermatol"},{"key":"2026072409174228700_llag132-B17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jid.2017.09.008","article-title":"Increased suicide risk in patients with hidradenitis suppurativa","volume":"138","author":"Thorlacius","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2026072409174228700_llag132-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1057\/s41599-025-04359-0","article-title":"Integrating psychological and mental health perspectives in disease management: improving patient well-being","volume":"12","author":"Grosso","year":"2025","journal-title":"Humanit Soc Sci Commun"},{"key":"2026072409174228700_llag132-B19","first-page":"729","volume-title":"Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach","author":"Hurley","year":"1989"},{"key":"2026072409174228700_llag132-B20","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/bjd.17508","article-title":"Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment","volume":"180","author":"Rondags","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026072409174228700_llag132-B21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2340\/00015555-2513","article-title":"Hurley staging refined: a proposal by the Dutch Hidradenitis Suppurativa Expert Group","volume":"97","author":"Horv\u00e1th","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2026072409174228700_llag132-B22","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1111\/bjd.15842","article-title":"A pilot study of fatigue in patients with hidradenitis suppurativa","volume":"178","author":"Riis","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026072409174228700_llag132-B23","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3390\/jcm14030910","article-title":"Impact of hidradenitis suppurativa on sexual quality of life","volume":"14","author":"Caliezi","year":"2025","journal-title":"J Clin Med"},{"key":"2026072409174228700_llag132-B24","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.16672","article-title":"A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026072409174228700_llag132-B25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00403-025-03943-3","article-title":"Comparing maximum and average numerical rating scale pain scores in hidradenitis suppurativa","volume":"317","author":"Li","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"2026072409174228700_llag132-B26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/bjd.16101","article-title":"Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa","volume":"178","author":"Ingram","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026072409174228700_llag132-B27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jamadermatol.2021.4741","article-title":"Patient impressions and outcomes after clinic-based hidradenitis suppurativa surgery","volume":"158","author":"Ravi","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2026072409174228700_llag132-B28"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag132\/67364646\/llag132.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/8\/1433\/67364646\/llag132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/8\/1433\/67364646\/llag132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:17:53Z","timestamp":1784899073000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/8\/1433\/8524556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,3,14]]},"published-print":{"date-parts":[[2026,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag132","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,3,14]]}}}